Becton, Dickinson and Company (BDX)
(Delayed Data from NYSE)
$237.84 USD
+0.54 (0.23%)
Updated Jul 29, 2024 04:00 PM ET
After-Market: $237.77 -0.07 (-0.03%) 7:58 PM ET
2-Buy of 5 2
B Value D Growth F Momentum D VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$237.84 USD
+0.54 (0.23%)
Updated Jul 29, 2024 04:00 PM ET
After-Market: $237.77 -0.07 (-0.03%) 7:58 PM ET
2-Buy of 5 2
B Value D Growth F Momentum D VGM
Zacks News
Based in Franklin Lakes, NJ, Becton, Dickinson and Company (BDX) commonly known as BD, is a medical technology company engaged principally in the development, manufacture and sale of medical devices, instrument systems and reagents. In fiscal 2019, BD’s revenues increased 8.2% to $17.29 billion. Earlier, BD’s operations consisted of three business segments: BD Medical, BD Diagnostics and BD Biosciences. However, the company’s organizational structure was realigned to form two principal business segments: BD Medical, BD Life Sciences and BD Interventional.
The Zacks Analyst Blog Highlights: Becton, Dickinson and Co, Abbott, Myomo and Apyx Medical
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Becton, Dickinson and Co, Abbott, Myomo and Apyx Medical
BD (BDX) Gets EUA, CE Mark for New Molecular Diagnostic Test
by Zacks Equity Research
BD's (BDX) new test has the capability to detect SARS-CoV-2 and Influenza A+B in a single test.
All You Need to Know About Becton Dickinson (BDX) Rating Upgrade to Buy
by Zacks Equity Research
Becton Dickinson (BDX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Align (ALGN) Extends Invisalign G8 Availability Worldwide
by Zacks Equity Research
Align's (ALGN) latest evolution in biomechanics is set to improve treatment predictability for frequently treated case types.
Becton Dickinson (BDX) Earnings Surpass Estimates in Q1
by Zacks Equity Research
Each of Becton Dickinson's (BDX) core units witnesses strong revenue growth in the fiscal first quarter.
Becton Dickinson (BDX) Surpasses Q1 Earnings and Revenue Estimates
by Zacks Equity Research
Becton Dickinson (BDX) delivered earnings and revenue surprises of 44.90% and 0.13%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?
Cardinal Health (CAH) to Post Q2 Earnings: What's in Store?
by Zacks Equity Research
Cardinal Health's (CAH) fiscal second-quarter results are likely to reflect solid performance in Pharmaceutical segment.
What's in Store for Meridian Bioscience's (VIVO) Q1 Earnings?
by Zacks Equity Research
Meridian Bioscience's (VIVO) fiscal first-quarter results are likely to reflect strong performance by Life Science business line.
AmerisourceBergen (ABC) to Post Q1 Earnings: What's in Store?
by Zacks Equity Research
AmerisourceBergen's (ABC) fiscal first-quarter results are likely to reflect solid performance at Pharmaceutical Distribution and Other units.
Baxter (BAX) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
Baxter's (BAX) fourth-quarter performance is likely to reflect growth in its Acute Therapies business.
3 MedTech Stocks Likely to Top Estimates This Earnings Season
by Urmimala Biswas
Strong signs of rebound in base sales volumes make us optimistic about VIVO, XRAY, and PDCO's results.
Becton Dickinson (BDX) Earnings Expected to Grow: What to Know Ahead of Q1 Release
by Zacks Equity Research
Becton Dickinson (BDX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
BD (BDX) Gears Up for Q1 Earnings: What's in the Offing?
by Zacks Equity Research
BD's (BDX) first-quarter fiscal 2021 results are likely to reflect strong year-over-year growth in revenues from assays in its Life Sciences segment.
Becton, Dickinson's (BDX) Shares March Higher, Can It Continue?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor in Becton, Dickinson and Company (BDX).
The Zacks Analyst Blog Highlights: Quest Diagnostics, Abbott, Becton, Dickinson and Co, Quidel and Hologic
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Quest Diagnostics, Abbott, Becton, Dickinson and Co, Quidel and Hologic
Federal, Private Tie-Ups Boost COVID-19 Testing Volume
by Urmimala Biswas
The Department of Health and Human Services (HHS) promises over $22 billion of funding.
BD (BDX) Posts Upbeat Preliminary Fiscal First Quarter Results
by Zacks Equity Research
BD (BDX) projects its fiscal Q1 revenues to surge from the year-ago figure, primarily on the back of high demand for its COVID-19 diagnostic tests
Testing Space in Focus Again Thanks to New Wave of Coronavirus
by Urmimala Biswas
The resurgence in coronavirus infections is drawing attention back to the diagnostic testing space.
Why Becton Dickinson (BDX) is Poised to Beat Earnings Estimates Again
by Zacks Equity Research
Becton Dickinson (BDX) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Here's Why You Should Invest in LHC Group (LHCG) Stock Now
by Zacks Equity Research
LHC Group (LHCG) continues to gain traction from its broad range of services, and strategic acquisitions and joint ventures.
AMN Healthcare (AMN) Releases Solid Preliminary Q4 Revenues
by Zacks Equity Research
AMN Healthcare (AMN) posts solid fourth-quarter 2020 revenue data on the back of strong demand for the company's services across its three segments.
The Zacks Analyst Blog Highlights: McKesson, Cardinal Health, Becton, Dickinson and Co and Hill-Rom Holdings
by Zacks Equity Research
The Zacks Analyst Blog Highlights: McKesson, Cardinal Health, Becton, Dickinson and Co and Hill-Rom Holdings
4 Dividend-Paying Undervalued MedTech Stocks for Gains in 2021
by Urmimala Biswas
Here we discuss four dividend-paying value stocks, MCK, CAH, BDX and HRC, which though trading cheap now, have solid chances of a rebound in the second half of 2021.
Why Is Becton Dickinson (BDX) Up 3.5% Since Last Earnings Report?
by Zacks Equity Research
Becton Dickinson (BDX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Should Value Investors Choose Becton, Dickinson (BDX) Stock?
by Zacks Equity Research
Let's see if Becton, Dickinson (BDX) stock is a good choice for value-oriented investors right now from multiple angles.